Drug intelligence / Profile preview

AstraProst

Development stage
Preclinical
Lead developer
Rigshospitalet
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

AstraProst (also known as [211At]AstraProst) is a preclinical-stage targeted alpha therapy (TAT) radiopharmaceutical being developed by TetraKit Technologies in collaboration with the University of Copenhagen and Rigshospitalet. It is designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). AstraProst consists of a glutamate-urea-lysine pharmacophore that targets prostate-specific membrane antigen (PSMA), radiolabeled with the alpha-emitting radionuclide astatine-211 (211At) using TetraKit's proprietary tetrazine ligation (click chemistry) platform. In preclinical studies, AstraProst demonstrated high binding affinity and internalization in PSMA-positive LNCaP cells, leading to delayed tumor growth and prolonged survival in tumor-bearing mice.

Other names
211At-AstraProstAstatine-211 AstraProstAstatine211 AstraProstAstatine 211 AstraProst[211At]AstraProst
02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
metastatic castration-resistant prostate cancer (mCRPC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • RigshospitaletLead developer
07

Patents & exclusivity

Patents
3

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
195
Drugs in the lead indication
614

Lead indication: metastatic castration-resistant prostate cancer (mCRPC)

Most advanced in the lead indication

  1. lutetium-177Approved
  2. lutetium-177 PSMAApproved
  3. lutetium Lu 177 PSMA radioligand therapyApproved
  4. 18F-PSMA-11Approved
  5. abirateroneApproved

Beyond the preview

Go deeper on AstraProst.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AstraProst.

Work on AstraProst? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call